Phathom Pharmaceuticals (NASDAQ:PHAT – Get Free Report) had its target price reduced by analysts at Barclays from $14.00 to $10.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s price target points to a potential upside of 96.85% from the company’s previous close.
A number of other equities research analysts have also commented on the stock. Leerink Partners initiated coverage on shares of Phathom Pharmaceuticals in a report on Wednesday, September 9th. They set a “market perform” rating and a $10.00 price objective on the stock. Citigroup reaffirmed a “buy” rating on shares of Phathom Pharmaceuticals in a research note on Friday, October 30th. Jefferies Financial Group reiterated a “buy” rating and set a $16.00 target price on shares of Phathom Pharmaceuticals in a report on Wednesday, October 14th. Craig Hallum reiterated a “buy” rating and set a $15.00 target price on shares of Phathom Pharmaceuticals in a report on Wednesday, October 21st. Finally, Needham & Company LLC dropped their price target on Phathom Pharmaceuticals from $28.00 to $22.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $19.67.
Read Our Latest Research Report on PHAT
Phathom Pharmaceuticals Stock Down 4.2%
Institutional Trading of Phathom Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the business. State of Alaska Department of Revenue acquired a new stake in shares of Phathom Pharmaceuticals in the third quarter valued at about $25,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Phathom Pharmaceuticals during the third quarter worth about $30,000. State of Wyoming bought a new stake in Phathom Pharmaceuticals during the first quarter worth about $55,000. Allworth Financial LP raised its holdings in Phathom Pharmaceuticals by 26.1% during the third quarter. Allworth Financial LP now owns 13,172 shares of the company’s stock worth $96,000 after acquiring an additional 2,729 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in Phathom Pharmaceuticals by 16.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 14,761 shares of the company’s stock valued at $109,000 after purchasing an additional 2,068 shares during the last quarter. Institutional investors own 99.01% of the company’s stock.
About Phathom Pharmaceuticals
Phathom Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. Founded in 2018, the company is based in Florham Park, New Jersey, and concentrates its commercial activities on the U.S. market. Its primary product is Voquezna (vonoprazan), an acid blocker used to treat certain conditions involving gastroesophageal reflux disease (GERD), including erosive esophagitis and heartburn associated with non-erosive GERD. Vonoprazan is also used with antibiotics to treat Helicobacter pylori infection.
Further Reading
- Five stocks we like better than Phathom Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Phathom Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phathom Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
